Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

We investigated the effects of pharmacogenetic variations and efavirenz pharmacokinetics on inter-individual differences in the extent of CYP3A induction by efavirenz using 4 beta-hydroxycholesterol/cholesterol (4 beta-OHC/Chol) as a marker for CYP3A induction. Plasma 4 beta-hydroxycholesterol and cholesterol concentrations were determined at baseline, and at the 4th, 16th and 48th week of efavirenz-based highly active antiretroviral therapy in antiretroviral therapy-naive HIV patients (n = 77). Efavirenz plasma concentrations were quantified at weeks 4 and 16. CYP2B6, CYP3A5, ABCB1, UGT2B7 genotyping were done. Compared with baseline, the median plasma 4 beta-OHC/Chol ratio increased at the 4th (257%), 16th (291%) and 48th (165%) week (P<0.0001). CYP2B6*6 genotype significantly influenced 4 beta-OHC/Chol ratio at weeks 16 (P = 0.02) and 48 (P = 0.04) being highest in CYP2B6*6/*6>*1/*6>*1/*1. There were positive correlations between plasma efavirenz and 4 beta-OHC/Chol ratios (week 4: P = 0.02, week 16: P = 0.001). CYP3A enzyme induction by efavirenz is pronounced in CYP2B6 slow metabolizers who have high efavirenz plasma exposure.